Bionano Genomics, Inc. reports developments in genome analysis solutions built around optical genome mapping (OGM), diagnostic services, software and nucleic acid extraction technologies. Company updates commonly address OGM applications in cytogenetics, rare disease research, hematologic malignancies, reproductive disorders and other genomic-analysis workflows, including published studies comparing OGM with karyotyping, FISH, chromosomal microarrays, next-generation sequencing and long-read sequencing.
Recurring news also covers financial results, revenue outlooks, scientific-meeting presentations, Bionano Symposium activity, use of VIA™ software, the Ionic® system and Bionano Laboratories diagnostic testing services. Governance updates include board and executive leadership changes at the Nasdaq-listed life sciences instrumentation company.
Bionano Genomics (BNGO) has announced the lineup for its upcoming virtual Symposium 2023, scheduled from January 23 to 26, 2023. The event will feature 30 oral presentations from 27 different customers, showcasing advancements in optical genome mapping (OGM) within genetic disease, cancer research, and cell bioprocessing. Attendees can participate in live panels and view 34 scientific posters. The CEO highlighted the event as a platform for collaboration and knowledge sharing in the OGM community. The company has reported significant workflow improvements, enhancing OGM's applicability in clinical research.
Bionano Genomics, Inc. (BNGO) released an interim report on its ongoing clinical trial for the prenatal genetic disease testing program. The study evaluated 200 samples from 123 unique cases across 9 sites. Key findings include:
- 56% of cases showed comparable results between the OGM analysis and two standard tests.
- 100% concordance with standard care for all samples and variant calls.
- 100% site-to-site reproducibility for analytical quality control.
The trial aims to position OGM as a cost-effective alternative in prenatal diagnostics, revealing promising results and potential next steps.
Bionano Genomics (BNGO) announced a collaboration with NVIDIA to create an acceleration platform for its optical genome mapping (OGM) workflow. This partnership aims to enhance data processing speed while minimizing costs related to secondary OGM data analysis. The platform is expected to support high-throughput workflows, processing up to 96 cancer workflows or over 300 whole genomes weekly. Bionano will showcase the solution at the AGBT General Meeting on February 6-9, 2023. The initiative is part of Bionano's strategy to expand into new research areas and improve healthcare outcomes.
Bionano Genomics (Nasdaq: BNGO) announced a study validating optical genome mapping (OGM) for identifying homologous recombination deficiency (HRD) in breast cancer samples. Published research indicates that OGM detected HRD effectively, showcasing superior sensitivity compared to whole genome sequencing (WGS). The study, conducted by Institut Curie on 15 triple negative breast carcinoma samples, highlights OGM's potential for capturing significant genomic alterations that WGS may miss. This advancement may enable better patient selection for PARP inhibitor treatments, potentially enhancing therapeutic outcomes.
Bionano Genomics (BNGO) will host its 2023 Symposium from January 23-26, focusing on optical genome mapping (OGM) applications in genetic diseases and cancer. Over 25 global researchers will present innovations and findings in four thematic areas: oncology, constitutional genetic diseases, and cell bioprocessing. The event aims to enhance understanding of genomic analysis tools and their integration into clinical research. Registration for the virtual symposium is free and open to all interested participants.
Bionano Genomics (BNGO) announced its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will showcase presentations from the leadership team and discussions with key opinion leaders in cancer and genetic disorders. A Q&A session will follow, allowing audience interaction. A live webcast will be available for registration through the company's website. Bionano focuses on genome analysis solutions, enhancing research in biology and medicine.
Bionano Genomics (BNGO) reported preliminary financial highlights for Q4 and full year 2022, expecting revenues between $8.1 million and $8.4 million, marking a 29% to 33% increase year-over-year. The installed base of Saphyr systems reached 240, a 46% jump from 2021. Overall, 2022 revenues are estimated at $27.7 million to $28 million, representing a 54% to 56% increase. The company achieved all its 2022 milestones, including launching new OGM laboratory tests and enhancing its DNA sample preparation workflow.
Bionano Genomics (BNGO) announced a peer-reviewed study recommending optical genome mapping (OGM) as a first-line analysis for acute myeloid leukemia (AML). Conducted by eight research institutes, the study found OGM to be superior and more cost-effective than traditional methods like karyotyping. Key findings included a 100% concordance with these methods, and OGM identified pathogenic variants in 12% of cases, which could alter risk levels or clinical trial eligibility. The results support OGM's potential as a standard of care for cytogenomic evaluation in AML.
Bionano Genomics (Nasdaq: BNGO) announced its participation in the ASH Annual Meeting from December 10-13, 2022, in New Orleans, Louisiana. The event will showcase the potential of optical genome mapping (OGM) technology in myeloid cancer and hematological research. Notable presentations include a workshop led by Dr. Rashmi Kanagal-Shamanna and four scientific posters focused on OGM applications in major blood disorders. The company’s CEO expressed enthusiasm about the growing adoption of OGM among researchers.
Bionano Genomics, Inc. (NASDAQ: BNGO) has announced a definitive agreement to acquire Purigen Biosystems, Inc. for up to $64 million. This acquisition includes the Ionic® Purification System and proprietary isotachophoresis (ITP) technology for improved nucleic acid isolation and purification, aimed at enhancing the optical genome mapping (OGM) process. The transaction is anticipated to close by December 8, 2022. Bionano expects the integration of Purigen's technology to simplify workflows and expand its sample prep capabilities, potentially accelerating OGM adoption in various research areas.